Targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the…

Continue Reading

News Source: medicalxpress.com